Advertisement
ALZN vs FTH
Which Stock Would AI Choose? Alzamend Neuro, Inc. (ALZN) vs. Faeth Therapeutics, Inc. (FTH) Stock Comparison
Key Takeaways
- ALZN (Alzamend Neuro, Inc.) is a micro-cap, clinical-stage biopharmaceutical company developing treatments for Alzheimer's disease and related neuropsychiatric disorders, with a market capitalization under roughly $10 million.
- FTH (Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics) is a clinical-stage oncology company focused on cancer therapies, with a market capitalization of roughly $500 million.
- Both names are pre-revenue biotechnology companies, but FTH holds a substantially larger cash position (about $186 million) versus a thinner balance sheet at ALZN.
- Tickeron AI Verdict: FTH is the favored ticker in this comparison, reflecting stronger momentum, broader analyst support, and a larger liquidity cushion relative to ALZN.
- Relative performance diverges sharply: FTH has posted strong year-to-date gains, while ALZN has contended with exchange-listing compliance and funding concerns.
- You can explore ALZN Major News and ALZN Today's Price Move, as well as FTH Major News and FTH Today's Price Move, for ongoing updates on each ticker.
- To see how automated systems are positioning across the market, explore Trending AI Robots.
Introduction
Investors evaluating clinical-stage biotechnology names often weigh momentum, catalysts, and balance-sheet strength alongside pure scientific promise. This stock comparison examines two Nasdaq-listed companies operating in very different corners of healthcare: ALZN (Alzamend Neuro, Inc.), which targets Alzheimer's disease and neuropsychiatric disorders, and FTH (Faeth Therapeutics, Inc.), which develops oncology therapeutics. Both are pre-revenue businesses, yet they occupy notably different positions in terms of scale, liquidity, and market sentiment. This comparison is most relevant to growth-oriented and event-driven traders and investors who track early-stage biotech names where clinical milestones and financing conditions can drive outsized relative performance.
ALZN Overview and Recent Performance
ALZN, Alzamend Neuro, Inc., is a clinical-stage biopharmaceutical company developing novel products for neurodegenerative and psychiatric disorders. Its lead program, AL001, is a lithium-based formulation being studied for Alzheimer's disease, bipolar disorder, post-traumatic stress disorder (PTSD), and major depressive disorder (MDD), while ALZN002 is an immunotherapy candidate for Alzheimer's-type dementia. Recent market activity has been volatile. The company has faced Nasdaq listing-compliance issues tied to minimum stockholders' equity requirements, and although it announced regaining compliance in recent months, funding and going-concern risks remain prominent themes in its filings. With a market capitalization of only a few million dollars and limited cash, ALZN carries elevated risk, though positive analyst actions and clinical data presentations have occasionally sparked sharp, short-lived rallies.
FTH Overview and Recent Performance
FTH, Faeth Therapeutics, Inc., is a clinical-stage biotechnology company developing cancer therapies. The company, previously known as Sensei Biotherapeutics, changed its name and ticker in June 2026. Its lead candidate, PIKTOR, is an investigational multi-node inhibitor of the PI3K/AKT/mTOR signaling pathway being developed for endometrial and breast cancers, with key Phase 2 data expected around year-end 2026. The pipeline also includes Solnerstotug, a VISTA-targeting antibody in Phase 1/2 for solid tumors. Recent weeks have featured preclinical data presentations at the ESMO (European Society for Medical Oncology) conference and a series of analyst initiations and reiterations, contributing to a strong consensus rating and notable relative momentum. A cash position of approximately $186 million provides a comparatively deep runway for continued clinical development.
Trending AI Robots
Tickeron operates a large ecosystem of automated trading systems, with hundreds of AI trading bots that collectively trade thousands of different tickers across varied strategies, timeframes, and performance profiles. Not all of these bots are equally suited to every market environment, which is why Tickeron curates a dedicated Trending AI Robots section. This page highlights only the bots whose recent performance and strategy alignment make them most appropriate for current conditions, giving traders a filtered view of what is working now. Because each bot differs in trading style, holding period, statistics, and the universe of tickers it covers, the section helps users identify systems matching their own objectives. Explore the Trending AI Robots page to review the latest leading strategies.
Head-to-Head Comparison
The two companies diverge most clearly on scale, liquidity, and market positioning. FTH operates with a market capitalization roughly 60 to 80 times larger than ALZN and carries a far more substantial cash balance, which reduces near-term financing risk. Growth drivers also differ: FTH is approaching a defined clinical catalyst in endometrial and breast cancer data, whereas ALZN remains earlier-stage with its Alzheimer's and psychiatric programs. On risk factors, ALZN faces heightened dilution and exchange-listing concerns, while FTH carries typical binary biotech event risk ahead of trial readouts. Sentiment also favors FTH, which holds a Strong Buy consensus among analysts, versus a more limited coverage base for ALZN.
Tickeron AI Verdict
Based on observable factors such as trend consistency, balance-sheet stability, catalyst proximity, and relative market positioning, Tickeron's AI would currently favor FTH over ALZN. The larger cash runway, more robust analyst coverage, and defined near-term clinical catalysts give FTH a comparatively stronger positioning profile, while ALZN remains more sensitive to financing and listing risks. This assessment reflects probabilistic, data-driven analysis of current conditions rather than a definitive forecast, and it should be understood as a relative comparison between two early-stage, high-risk equities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALZN is a Hold and FTH is a Hold.
Momentum Indicator for ALZN turns positive, indicating new upward trend
ALZN saw its Momentum Indicator move above the 0 level on November 03, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 72 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALZN just turned positive on October 30, 2026. Looking at past instances where ALZN's MACD turned positive, the stock continued to rise in 32 of 38 cases over the following month. The odds of a continued upward trend are 84%.
Following a +6.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALZN advanced for three days, in 174 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALZN moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 20 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 38 cases where ALZN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
ALZN moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALZN crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALZN broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALZN entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. ALZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-0.695) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FTH in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 09, 2026
FTH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 34 cases where FTH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +3.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTH advanced for three days, in 169 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 45 cases where FTH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FTH as a result. In 84 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for FTH turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 42 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for FTH entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. FTH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.294) is normal, around the industry mean (3.498). P/E Ratio (-0.362) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
| ALZN | FTH | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 76% | 2 days ago 89% |
| Advances ODDS (%) | 7 days ago 81% | 8 days ago 83% |
| Declines ODDS (%) | 21 days ago 90% | 13 days ago 89% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALZN’s FA Score shows that 0 FA rating(s) are green while FTH’s FA Score has 1 green FA rating(s).
- ALZN’s FA Score: 0 green, 5 red.
- FTH’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALZN’s TA Score shows that 3 TA indicator(s) are bullish while FTH’s TA Score has 3 bullish TA indicator(s).
- ALZN’s TA Score: 3 bullish, 7 bearish.
- FTH’s TA Score: 3 bullish, 5 bearish.
Price Growth
ALZN (@Biotechnology) experienced а -7.53% price change this week, while FTH (@Biotechnology) price change was -34.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ALZN is expected to report earnings on Dec 08, 2026.
FTH is expected to report earnings on Apr 01, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALZN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALZN has been loosely correlated with VRAX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ALZN jumps, then VRAX could also see price increases.
| Ticker / NAME | Correlation To ALZN | 1D Price Change % | ||
|---|---|---|---|---|
| ALZN | 100% | -5.92% | ||
| VRAX - ALZN | 46% Loosely correlated | -9.27% | ||
| FTH - ALZN | 41% Loosely correlated | +1.89% | ||
| ASBP - ALZN | 38% Loosely correlated | +0.06% | ||
| LTRN - ALZN | 36% Loosely correlated | -22.70% | ||
| SILO - ALZN | 33% Loosely correlated | +9.82% | ||
More | ||||
FTH and
Correlation & Price change
A.I.dvisor indicates that over the last year, FTH has been loosely correlated with VSTM. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if FTH jumps, then VSTM could also see price increases.
| Ticker / NAME | Correlation To FTH | 1D Price Change % | ||
|---|---|---|---|---|
| FTH | 100% | +1.89% | ||
| VSTM - FTH | 47% Loosely correlated | +0.34% | ||
| ALZN - FTH | 40% Loosely correlated | -5.92% | ||
| MOLN - FTH | 39% Loosely correlated | +4.84% | ||
| ZURA - FTH | 37% Loosely correlated | +13.31% | ||
| INAB - FTH | 37% Loosely correlated | -4.27% | ||
More | ||||